Author | Charles L. Vogel, MD, FACP

Articles

Commentary (Vogel): Trastuzumab in Breast Cancer

August 01, 2004

There is little that can be done toimprove on this excellentreview by Emensand Davidson.In particular, the section on the preclinicalpharmacology of trastuzumab(Herceptin) provides a concise summaryof the multiplicity of mechanismsattributable to this fascinatingcompound. One of those mechanisms-its immunomodulatory effectthrough antibody-dependent cell-mediatedcytotoxicity-has led not onlyto clinical trials of interleukin-2 (Pro-leukin), as cited by the authors, but toother investigative approaches as well.

HER2 Testing and Correlation With Efficacy of Trastuzumab Therapy

October 01, 2002

The emerging era of targeted cancer therapies has focused laboratory scientists and clinicians on the need to define and understand molecular targets of novel drugs. For breast cancer patients and doctors, this trend is not news-efforts have been under way for decades to identify the estrogen and progesterone receptors and define the value of these markers as predictors of response to hormonal therapy.

Systemic Therapy for Older Women With Breast Cancer

March 01, 2001

This superb review by Drs. Kimmick and Muss clearly and concisely summarizes the literature on the prevention and treatment of breast cancer in "older" women.

Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer

March 02, 1998

Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)-positive or -unknown metastatic breast cancer. Phase II and III trials have demonstrated that first-line therapy with toremifene, 60 mg/d, is as effective and as well tolerated as tamoxifen (Nolvadex), 20 or 40 mg/d, in such patients.